Tan EY - Search Results

1

Comparative Bioavailability of a Single Dose of Trametinib (TMT212) Containing 9% vs 11% Dimethyl Sulfoxide in Randomized Healthy Volunteers to Assess Long-Term Storage at Room Temperature.

Tan EY, Chiparus O, Choudhury S, Kim C, Lau M, Ziltener C, Ilankumaran P. Tan EY, et al. Clin Pharmacol Drug Dev. 2022 Oct;11(10):1203-1210. doi: 10.1002/cpdd.1129. Epub 2022 Jun 23. Clin Pharmacol Drug Dev. 2022. PMID: 35736001 Free PMC article. Clinical Trial.

2

Evaluation of a Low-Fat Low-Calorie Meal on the Relative Bioavailability of Trametinib and Dabrafenib: Results From a Randomized, Open-Label, 2-Part Study in Healthy Participants.

Tan EY, Pazdirkova M, Taylor AJ, Singh N, Iyer GR. Tan EY, et al. Clin Pharmacol Drug Dev. 2023 Mar;12(3):333-342. doi: 10.1002/cpdd.1220. Epub 2023 Jan 20. Clin Pharmacol Drug Dev. 2023. PMID: 36662829 Clinical Trial.

3

Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors.

Sarantopoulos J, Goel S, Chung V, Munster P, Pant S, Patel MR, Infante J, Tawbi H, Becerra C, Bruce J, Kabbinavar F, Lockhart AC, Tan E, Yang S, Carlson G, Scott JW, Sharma S. Sarantopoulos J, et al. Cancer Chemother Pharmacol. 2016 Nov;78(5):921-927. doi: 10.1007/s00280-016-3122-7. Epub 2016 Sep 28. Cancer Chemother Pharmacol. 2016. PMID: 27681579 Clinical Trial.

4

A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors.

de Weger VA, Goel S, von Moos R, Schellens JHM, Mach N, Tan E, Anand S, Scott JW, Lassen U. de Weger VA, et al. Cancer Chemother Pharmacol. 2018 Jan;81(1):73-80. doi: 10.1007/s00280-017-3469-4. Epub 2017 Nov 3. Cancer Chemother Pharmacol. 2018. PMID: 29101463

5

Exploratory Food Effect Assessment in Patients in Early Clinical Development of Oncology Drugs.

Ji Y, Tan E, Hengelage T, Quinlan M, Hendriks BS. Ji Y, et al. Clin Pharmacol Ther. 2023 Aug;114(2):288-302. doi: 10.1002/cpt.2911. Epub 2023 May 26. Clin Pharmacol Ther. 2023. PMID: 37078098 Review.

6

A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258).

Infante JR, Ramanathan RK, George D, Tan E, Quinlan M, Liu A, Scott JW, Sharma S. Infante JR, et al. Cancer Chemother Pharmacol. 2015 Apr;75(4):729-37. doi: 10.1007/s00280-015-2681-3. Epub 2015 Feb 4. Cancer Chemother Pharmacol. 2015. PMID: 25648347 Clinical Trial.

7

Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma.

Bouffet E, Geoerger B, Moertel C, Whitlock JA, Aerts I, Hargrave D, Osterloh L, Tan E, Choi J, Russo M, Fox E. Bouffet E, et al. J Clin Oncol. 2023 Jan 20;41(3):664-674. doi: 10.1200/JCO.22.01000. Epub 2022 Nov 14. J Clin Oncol. 2023. PMID: 36375115 Free PMC article. Clinical Trial.

8

Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study.

Tan DS, Leighl NB, Riely GJ, Yang JC, Sequist LV, Wolf J, Seto T, Felip E, Aix SP, Jonnaert M, Pan C, Tan EY, Ko J, Moody SE, Kim DW. Tan DS, et al. Among authors: tan ey. Lancet Respir Med. 2020 Jun;8(6):561-572. doi: 10.1016/S2213-2600(19)30267-X. Epub 2020 Jan 15. Lancet Respir Med. 2020. PMID: 31954624 Clinical Trial.

9

A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors.

Duca M, Lim DW, Subbiah V, Takahashi S, Sarantopoulos J, Varga A, D'Alessio JA, Abrams T, Sheng Q, Tan EY, Rosa MS, Gonzalez-Maffe J, Sand-Dejmek J, Fabre C, Martin M. Duca M, et al. Among authors: tan ey. Mol Cancer Ther. 2022 Apr 1;21(4):625-634. doi: 10.1158/1535-7163.MCT-21-0652. Mol Cancer Ther. 2022. PMID: 35131875 Clinical Trial.

10

Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions.

Xia B, Heimbach T, Lin TH, He H, Wang Y, Tan E. Xia B, et al. Cancer Chemother Pharmacol. 2012 Jun;69(6):1567-82. doi: 10.1007/s00280-012-1863-5. Epub 2012 Apr 11. Cancer Chemother Pharmacol. 2012. PMID: 22526410

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

177 results

Search Page

Filters